Meanwhile, mTOR inhibitors have several other effects (Li et al., 2014); in terms of safety, mTOR inhibitors have proven relatively safe long-term oral agents in human solid organ transplantation and tuberous sclerosis (Somers and Paul, 2015; Ventura-Aguiar et al., 2016). This evidence concerns the gene MTOR and tuberous sclerosis.